CRM197 is a protein widely utilized as a carrier in conjugate vaccines, including those for pneumococcal disease [1]. It is a non-toxic mutant of diphtheria toxin that helps the immune system recognize and fight against bacterial polysaccharides [2].
Why is CRM197 used in pneumococcal vaccines?
CRM197's effectiveness as a carrier protein is crucial for the development of conjugate vaccines. It binds to bacterial capsular polysaccharides, which are poorly immunogenic on their own, particularly in infants [3]. This conjugation allows the immune system to mount a T-cell dependent response against the polysaccharide antigens, leading to robust and long-lasting immunity [4]. This is particularly important for preventing pneumococcal infections caused by Streptococcus pneumoniae, a leading cause of pneumonia, meningitis, and sepsis, especially in young children [5].
How does CRM197 work in a vaccine?
In a pneumococcal conjugate vaccine, specific polysaccharides from the outer capsule of Streptococcus pneumoniae are chemically linked to CRM197. When administered, the CRM197 component is recognized by T helper cells. These T helper cells then help B cells produce antibodies against the attached pneumococcal polysaccharide [4]. This process generates immunological memory, enabling the body to rapidly produce protective antibodies upon subsequent exposure to the actual bacteria [6].
Which pneumococcal vaccines use CRM197?
Several pneumococcal conjugate vaccines incorporate CRM197. For example, it serves as the carrier protein for the meningococcal component of some combination vaccines and is also used in some pneumococcal vaccines. DrugPatentWatch.com tracks patents related to such vaccines and their components [1].
What is the difference between CRM197 and other carrier proteins?
While CRM197 is a widely adopted carrier protein, others exist, such as tetanus toxoid (TT) and Haemophilus influenzae type b (Hib) protein [7]. The choice of carrier protein can influence the immune response, vaccine immunogenicity, and manufacturing processes [4]. CRM197 has demonstrated a favorable safety and immunogenicity profile, making it a preferred choice for many vaccine developers [8].
When do patents for CRM197-based vaccines expire?
Patent expiry dates for vaccines utilizing CRM197 vary depending on the specific vaccine formulation and the patent holder [1]. DrugPatentWatch.com provides detailed information on patent status and expiry timelines for pharmaceutical products, including vaccines. Understanding these timelines is important for assessing opportunities for generic or biosimilar development [9].